Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iressa Use Should Not Be Limited By EGFR Mutation Testing, Researchers Say

Executive Summary

Data suggesting that the efficacy of Iressa is associated with an EGFR gene mutation should not stem use of anti-EGFR agents in mutation-negative patients, researchers said

You may also be interested in...



Iressa Access Program Might Answer Efficacy Questions, Researchers Say

AstraZeneca's database from the Iressa expanded access program could confirm whether patients with an EGFR mutation are more likely to benefit from therapy, researchers said

Iressa Access Program Might Answer Efficacy Questions, Researchers Say

AstraZeneca's database from the Iressa expanded access program could confirm whether patients with an EGFR mutation are more likely to benefit from therapy, researchers said

Genentech/OSI Tarceva Shows Two-Month Survival Improvement Over Placebo

Genentech/OSI's anti-EGFR agent Tarceva is associated with a two-month improvement in survival for refractory non-small cell lung cancer patients, according to pivotal trial data presented at the American Society of Clinical Oncology annual meeting in New Orleans June 7

Related Content

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel